Gaithersburg, MD, United States of America

Reena Varkey

USPTO Granted Patents = 12 (Patent Applications = 6)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 9)

Average Co-Inventor Count = 10.4

ph-index = 3

Forward Citations = 29(Granted Patents)

Company Filing History:

Boston Pharmaceuticals, Inc.

patents

1 out of 4,177

Abbott Laboratories Corporation

patents

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12428473 - Combination therapies using anti-pseudomonas PSL and PCRV binding molecules (2025-09-30),

2. 11912782 - BCMA monoclonal antibody-drug conjugate (2024-02-27),

3. 11529415 - Antibodies specific for IL-21 and uses thereof (2022-12-20),

4. 11203633 - Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas perv (2021-12-21),

5. 10988546 - BCMA monoclonal antibody-drug conjugate (2021-04-27),

6. 10775388 - Methods of using antibodies to determine periostin levels in a sample (2020-09-15),

7. 10597439 - Combination therapies using anti-pseudomonas PSL and PCRV binding molecules (2020-03-24),

8. 10588969 - Antibodies specific for IL-21 and uses thereof (2020-03-17),

9. 10022443 - Antibodies specific for IL-21 and uses thereof (2018-07-17),

10. 9862762 - Monoclonal antibodies which bind human periostin (2018-01-09),

11. 9580509 - Multispecific and multivalent binding proteins and uses thereof (2017-02-28),

12. 9527905 - [object Object] (2016-12-27),

Title: Reena Varkey: Innovator in Monoclonal Antibody Research

Introduction

Reena Varkey, a prominent inventor based in Gaithersburg, MD, has made significant contributions to the field of monoclonal antibody research, holding a total of 11 patents. Her innovative work focuses on advancing treatment options for various diseases, particularly those related to autoimmune and inflammatory conditions.

Latest Patents

Among her latest patents, Varkey has developed the BCMA monoclonal antibody-drug conjugate. This groundbreaking disclosure encompasses an antibody-drug conjugate (ADC) that targets B-cell maturation antigen (BCMA) and is conjugated to a cytotoxin. The invention outlines methods for effectively killing multiple myeloma cells, including stem cells that express BCMA.

Another notable patent involves antibodies specific for IL-21. This invention provides binding molecules, such as anti-IL-21 antibodies, that can inhibit or antagonize IL-21 activity. The technology is aimed at diagnosing and treating diseases associated with IL-21-mediated signal transduction, including Graft-versus-host disease (GVHD).

Career Highlights

Reena Varkey has worked with reputable companies in the biopharmaceutical industry, including MedImmune Limited and Boston Pharmaceuticals, Inc. Her experience in these organizations has undoubtedly enhanced her expertise and innovation in the field of immunology.

Collaborations

In her endeavors, Varkey has collaborated with esteemed professionals such as Partha S. Chowdhury and Melissa Marie Damschroder. These collaborations have played a crucial role in advancing her research and developing impactful therapeutic solutions.

Conclusion

Reena Varkey continues to be a vital player in the science of monoclonal antibodies. Her inventive spirit and dedication to research are paving the way for new treatments that could significantly improve patient outcomes in various diseases. Through her patents and collaborations, she exemplifies the role of innovation in the healthcare sector.

This text is generated by artificial intelligence and may not be accurate.